港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

勁方醫藥-B

32.800

-1.120-3.30%

成交量：75.64萬

成交額：2,497.92萬

市值：125.95億

市盈率：-5.40

高：33.900

開：33.660

低：32.380

收：33.920

52周最高：52.900

52周最低：19.600

股本：3.84億

香港流通股本：3.52億

量比：0.60

換手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):-6.070

淨資產收益率：--

總資產收益率：-12.49%

市淨率：5.95

市盈率(LYR):-5.40

市銷率: 82.94

資料載入中...

總覽公司新聞資訊公告

勁方醫藥公布2026中期業績：現金儲備近18億元，多靶點、多類型全域RAS療法及聯合方案面向胰腺癌、惡病質等大適應症市場

勁方醫藥-B(02595.HK)發布中期業績淨虧損2.2億元按年收窄68.48%

《業績》勁方醫藥(02595.HK)中期虧損收窄至2.2億人幣

阿斯达克财经

勁方醫藥-B（02595）發布2026年中期業績：收入4.25億元研發投入繼續加碼

勁方醫藥-B：2026年上半年營收達4247萬元人民幣

勁方醫藥－Ｂ(02595)股價上升5.009%，現價港幣$34.38

阿斯达克财经

勁方醫藥－Ｂ(02595)股價顯著上升14.899%，現價港幣$34.24

阿斯达克财经

港股異動 | 勁方醫藥-B(02595.HK)盤中升逾9% GFH375兩款全球首創胰腺癌聯合療法邁入II期研究

勁方醫藥-B(02595)：GFH375 兩款全球首創胰腺癌聯合療法邁入II期研究包括RAS靶向藥聯合惡病質雙抗方案及不同作用機制的RAS抑制劑雙聯方案

Wellington Management Group LLP增持勁方醫藥-B(02595.HK)2.88萬股每股作價約31.48港元

勁方醫藥-B：Wellington Management Group LLP增持，好倉比例升至7.0%

財報前瞻｜勁方醫藥-B本季度營收預計待披露，機構觀點偏謹慎

港股異動 | 勁方醫藥-B(02595.HK)漲近4% GFH375在國內進入單藥治療非小細胞肺癌註冊性III期臨床研究

勁方醫藥-B(02595.HK)：全球首個口服KRAS G12D抑制劑治療非小細胞肺癌III期研究啓動，GFH375第二項註冊性臨床研究完成首例患者入組

勁方醫藥-B（02595.HK）：GFH375進入中國KRAS G12D突變非小細胞肺癌註冊性III期臨床研究

勁方醫藥－Ｂ(02595)股價上升8.535%，現價港幣$30.52

阿斯达克财经

勁方醫藥-B(02595.HK)擬8月21日舉行董事會會議以審批中期業績

勁方醫藥科技（上海）股份有限公司（02595）擬於2026年8月21日審議中期業績

勁方醫藥-B 7月股份變動月報：H股新發行13,600,000股

異動解讀｜勁方醫藥-B盤中上漲5.45%，報28.24港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02595/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"勁方醫藥-B","latestPrice":32.8,"timestamp":1787556841714,"preClose":33.92,"halted":0,"volume":756400,"delay":0,"changeRate":-0.03301886792452843,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"交易中","change":-1.12,"latestTime":"08-24 15:34:25","open":33.66,"high":33.9,"low":32.38,"amount":24979238,"amplitude":0.044811,"askPrice":32.98,"askSize":2800,"bidPrice":32.76,"bidSize":3800,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787559000000},"marketStatusCode":2,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.92,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":0.60056,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":352000000,"roa":"-12.49%","roe":"--","lyrEps":-6.07,"volumeRatio":0.60056,"shares":384000000,"dividePrice":0,"high":33.9,"amplitude":0.044811,"preClose":33.92,"low":32.38,"week52Low":19.6,"pbRate":"5.95","psRate":"82.94","week52High":52.9,"institutionHeld":0,"latestPrice":32.8,"committee":0.151515,"eps":-6.07,"divideRate":0,"volume":756400,"delay":0,"ttmEps":-3.946,"open":33.66,"prevYearClose":23.78,"prevWeekClose":33.92,"prevMonthClose":27.74,"prevQuarterClose":29.44,"fiveDayClose":31.14,"twentyDayClose":33.18,"sixtyDayClose":33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null},{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1785513600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-08-21","current":-8.413583,"percent":0.73991,"low":-19.62221,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"high":-5.69787,"avg":-9.583629,"sd":2.661362,"marketCap":12562836089},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105},{"date":"2026-05-29","current":-8.035507,"twenty":-11.019944,"median":-10.082937,"eighty":-8.624127,"marketCap":12636909415},{"date":"2026-06-05","current":-6.909175,"twenty":-10.994143,"median":-10.039967,"eighty":-8.441141,"marketCap":10881371589},{"date":"2026-06-12","current":-6.584396,"twenty":-10.981505,"median":-9.989391,"eighty":-8.291507,"marketCap":10362858307},{"date":"2026-06-18","current":-6.718884,"twenty":-10.969649,"median":-9.941921,"eighty":-8.193596,"marketCap":10599892950},{"date":"2026-06-26","current":-5.732708,"twenty":-10.937065,"median":-9.927249,"eighty":-8.035507,"marketCap":8999909109},{"date":"2026-07-03","current":-7.180567,"twenty":-10.922684,"median":-9.900616,"eighty":-7.915515,"marketCap":11281367549},{"date":"2026-07-10","current":-9.054005,"twenty":-10.894174,"median":-9.893411,"eighty":-7.915515,"marketCap":14207263926},{"date":"2026-07-17","current":-8.396292,"twenty":-10.887172,"median":-9.884317,"eighty":-7.956496,"marketCap":13222088691},{"date":"2026-07-24","current":-8.187485,"twenty":-10.884642,"median":-9.862553,"eighty":-8.009423,"marketCap":12896166056},{"date":"2026-07-31","current":-6.510345,"twenty":-10.870773,"median":-9.833804,"eighty":-7.907869,"marketCap":10273970316},{"date":"2026-08-07","current":-7.003679,"twenty":-10.846908,"median":-9.792157,"eighty":-7.575355,"marketCap":11073962237},{"date":"2026-08-14","current":-7.214728,"twenty":-10.805358,"median":-9.754197,"eighty":-7.296139,"marketCap":11422106869},{"date":"2026-08-21","current":-7.917767,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"marketCap":12562836089}],"updateTime":1787542480744},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661257337","title":"勁方醫藥公布2026中期業績：現金儲備近18億元，多靶點、多類型全域RAS療法及聯合方案面向胰腺癌、惡病質等大適應症市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2661257337","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661257337?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 13:57","pubTimestamp":1787291820,"startTime":"0","endTime":"0","summary":"依据弗若斯特沙利文数据，劲方医药拥有全球最全面RAS疗法矩阵之一。目前劲方医药已开发多靶点、多分子形态、一线至各线疗法的全局RAS疗法矩阵，在该赛道有显著的协同、时间、成本优势。全球最全面RAS靶向疗法矩阵之一，面向十年内肿瘤靶向药增速最快赛道 RAS 突变在全球癌症患者中发生率高达30% 。多项单药或联合疗法方案将进一步巩固本公司在RAS靶向疗法赛道的深耕优势、拓宽未来的大适应症商业化协同空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5031198_ZH31198_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5031198_ZH31198_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","02595","BK1161","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251759","title":"勁方醫藥-B(02595.HK)發布中期業績 淨虧損2.2億元 按年收窄68.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251759","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661251759?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 12:09","pubTimestamp":1787285342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02595","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661725177","title":"《業績》勁方醫藥(02595.HK)中期虧損收窄至2.2億人幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2661725177","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661725177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 12:06","pubTimestamp":1787285160,"startTime":"0","endTime":"0","summary":"劲方医药-B(02595.HK) 公布2026年6月底止六个月中期业绩，收入4,247万元人民币(下同)，按年跌52.1%。亏损收窄至2.2亿元，上年同期亏损6.99亿元；每股亏损59分。不派息。(da)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-20 16:25。)过往派息公布日期派息事项派息内容2026/03/25末期业绩无派息AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260730163037115_s.jpeg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260730163037115_s.jpeg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539849/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539849/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","159938","BK1515","02595","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146926121","title":"勁方醫藥-B（02595）發布2026年中期業績：收入4.25億元 研發投入繼續加碼","url":"https://stock-news.laohu8.com/highlight/detail?id=1146926121","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146926121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 12:05","pubTimestamp":1787285134,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司8月21日公布截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司实现收入42,473千元人民币，较上年同期的88,744千元人民币下降；其他收入及收益40,619千元人民币，同比增加396.56%。报告期内，劲方医药-B的研发开支为192,528千元人民币，高于去年同期的122,435千元人民币；行政开支降低至27,295千元人民币，上年同期为36,952千元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110903702","title":"勁方醫藥-B：2026年上半年營收達4247萬元人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=1110903702","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110903702?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 12:03","pubTimestamp":1787284988,"startTime":"0","endTime":"0","summary":"劲方医药-B（Genfleet Therapeutics (Shanghai)）披露了截至2026年6月30日的六个月财务数据。报告期内，该公司录得营业收入4247万元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661022251","title":"勁方醫藥－Ｂ(02595)股價上升5.009%，現價港幣$34.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2661022251","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661022251?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 11:57","pubTimestamp":1787284620,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午11:57比前收市价上升5.009%，现股价为港币$34.38。至目前为止，今日最高价为$34.38，而最低价为$31.82。总成交量为74.42万股，总成交金额为港币$2.455千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608212413/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608212413/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02595","BK1161","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660579470","title":"勁方醫藥－Ｂ(02595)股價顯著上升14.899%，現價港幣$34.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2660579470","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660579470?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:55","pubTimestamp":1787194500,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午10:55比前收市价显著上升14.899%，现股价为港币$34.24。至目前为止，今日最高价为$34.24，而最低价为$30.56。总成交量为160.2万股，总成交金额为港币$5.171千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608202601/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608202601/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","09939","BK1574","BK1161","02595","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660470368","title":"港股異動 | 勁方醫藥-B(02595.HK)盤中升逾9% GFH375兩款全球首創胰腺癌聯合療法邁入II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2660470368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660470368?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:45","pubTimestamp":1787193956,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02595","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660471531","title":"勁方醫藥-B(02595)：GFH375 兩款全球首創胰腺癌聯合療法邁入II期研究 包括RAS靶向藥聯合惡病質雙抗方案及不同作用機制的RAS抑制劑雙聯方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2660471531","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660471531?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 08:10","pubTimestamp":1787184633,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，董事会欣然宣布一项GFH375的三臂平行对照II期临床研究已于近期启动。GFH375将进入两款全新联合疗法对照单药治疗的II 期研究，治疗KRAS G12D 突变型经治局部晚期不可切除或转移性胰腺癌患者。KRAS G12D 突变在胰腺癌患者中发生率约40%，同时胰腺癌患者的恶病质发生率居于所有瘤种之首、超过60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159938","09939","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482535","title":"Wellington Management Group LLP增持勁方醫藥-B(02595.HK)2.88萬股 每股作價約31.48港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482535","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482535?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:22","pubTimestamp":1786965727,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02595","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156453150","title":"勁方醫藥-B：Wellington Management Group LLP增持，好倉比例升至7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156453150","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156453150?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:11","pubTimestamp":1786957910,"startTime":"0","endTime":"0","summary":"Wellington Management Group LLP于2026年8月13日以每股均价31.4819港元买入劲方医药-B股份2.88万股，涉资约90.67万港元。Wellington Management Group LLP此次增持前持有劲方医药-B好仓2459.98万股，占比6.99%；增持后持股量为2462.86万股，好仓比例升至7.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136722045","title":"財報前瞻｜勁方醫藥-B本季度營收預計待披露，機構觀點偏謹慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1136722045","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136722045?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 08:46","pubTimestamp":1786668364,"startTime":"0","endTime":"0","summary":"劲方医药-B将于2026年08月21日发布最新季度财报，市场关注临床推进与费用控制对单季亏损的影响及毛利率趋势。由于缺乏覆盖机构在公开渠道披露的本季度一致预期与公司指引，当前市场对劲方医药-B本季度的营收、毛利率、净利润或净利率、调整后每股收益的量化预测暂未形成共识。对劲方医药-B而言，若本季度维持积极推进关键研究节点，短期利润表仍将承压，但也可能带来合作里程碑或授权金的阶段性确认，形成对收入与毛利率的短期支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜劲方医药-B本季度营收预计待披露，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658072876","title":"港股異動 | 勁方醫藥-B(02595.HK)漲近4% GFH375在國內進入單藥治療非小細胞肺癌註冊性III期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658072876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658072876?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 13:44","pubTimestamp":1786340676,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02595","BK1161","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605432","title":"勁方醫藥-B(02595.HK)：全球首個口服KRAS G12D抑制劑治療非小細胞肺癌III期研究啓動，GFH375第二項註冊性臨床研究完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605432?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:13","pubTimestamp":1786320788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","BK1574","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109928638","title":"勁方醫藥-B（02595.HK）：GFH375進入中國KRAS G12D突變非小細胞肺癌註冊性III期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1109928638","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109928638?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:02","pubTimestamp":1786320128,"startTime":"0","endTime":"0","summary":"劲方医药-B（GENFLEET-B，股票代码：02595）宣布，其核心在研药物GFH375正式迈入中国注册性III期临床研究阶段，针对的适应症为KRAS G12D突变型非小细胞肺癌（NSCLC）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657180486","title":"勁方醫藥－Ｂ(02595)股價上升8.535%，現價港幣$30.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2657180486","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657180486?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 15:29","pubTimestamp":1786087740,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在下午03:29比前收市价上升8.535%，现股价为港币$30.52。至目前为止，今日最高价为$30.52，而最低价为$28.16。总成交量为138.28万股，总成交金额为港币$4.025千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608072621/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608072621/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","159938","09939","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572325","title":"勁方醫藥-B(02595.HK)擬8月21日舉行董事會會議以審批中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572325","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572325?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 06:57","pubTimestamp":1785970621,"startTime":"0","endTime":"0","summary":"格隆汇8月6日丨劲方医药-B(02595.HK)宣布，公司将于2026年8月21日(星期五)举行董事会会议，旨在(其中包括)审议及批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，以及考虑派发中期股息(如有)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260806/32327143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","159938","BK1515","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188216906","title":"勁方醫藥科技（上海）股份有限公司（02595）擬於2026年8月21日審議中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1188216906","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188216906?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 06:05","pubTimestamp":1785967540,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（02595）6日公告，公司董事会将于2026年8月21日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并将同时考虑是否派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178217906","title":"勁方醫藥-B 7月股份變動月報：H股新發行13,600,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1178217906","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178217906?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:22","pubTimestamp":1785921732,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年8月5日发布截至2026年7月31日的证券变动月报表，披露了报告期内股本变动及相关信息。公司普通股H股在香港联交所上市，面值为每股人民币0.1元。截至本月末，已发股本总额为人民币38,396,663元。根据月报，本月新增H股主要来自于2026年7月17日完成的一次配售发行，共计13,600,000股，发行价格为每股港币34.69元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138812924","title":"異動解讀｜勁方醫藥-B盤中上漲5.45%，報28.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138812924","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138812924?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:32","pubTimestamp":1785465135,"startTime":"0","endTime":"0","summary":"7月31日，劲方医药-B盘中上涨5.45%，报28.24港元/股，成交额2757.3万港元。劲方医药-B所在的生物科技行业中，个股中，信达生物跌0.06%，康方生物涨2.09%，百济神州跌0.61%，三生制药跌2.3%，科伦博泰生物涨1.7%。劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司，主要为肿瘤、自身免疫性疾病和炎症性疾病提供新型治疗方案，研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发等环节。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":122,"code":"91000000","status":"200"}]}}